Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
Hepatology (Baltimore, Md.)|December 19, 2024
International trends in biliary tract cancer-related mortality, 2000-2022: An observational study of the World Health Organization Mortality DatabaseQuynh Thi Vu, Yoshito Nishimura, Ko Harada, et al.
The Annals of Pharmacotherapy|February 27, 2023
Proton Pump Inhibitors and Rhabdomyolysis: Analysis of Two Different Cross-Sectional DatabasesSatoru Mitsuboshi, Hirofumi Hamano, Yurika Kuniki, et al.
International Journal of Clinical Pharmacy|April 17, 2024
Adverse events of nivolumab plus ipilimumab versus nivolumab plus cabozantinib: a real-world pharmacovigilance studyYurie Oka, Jun Matsumoto, Tatsuaki Takeda, et al.
Molecular Cancer Research : MCR|November 23, 2018
Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in <i>EGFR</i>-Mutant Non-Small Cell Lung Cancer CellsKei Namba, Kazuhiko Shien, Yuta Takahashi, et al.
Journal of Clinical Medicine|July 15, 2026
Changing Trends in Cardiovascular Disease Burden in North Africa and the Middle East, 1990-2023: A Joinpoint Analysis of GBD 2023 DataHanane Ouddoud, Judah Israel Ong Lescano, Keith Pardillada Belangoy, et al.
JAMA Otolaryngology-- Head & Neck Surgery|June 25, 2026
International Trends in Head and Neck Cancer MortalityTsukasa Higashionna, Tatsuaki Takeda, Mariko Fujii, et al.
Cancer Science|June 5, 2019
Acquired resistance mechanisms to afatinib in HER2-amplified gastric cancer cellsTakahiro Yoshioka, Kazuhiko Shien, Tatsuaki Takeda, et al.
Cancer Science|March 14, 2018
Therapeutic strategies for afatinib-resistant lung cancer harboring HER2 alterationsHidejiro Torigoe, Kazuhiko Shien, Tatsuaki Takeda, et al.
Clinical Rheumatology|March 6, 2026
Global trends in systemic sclerosis-related mortality, 2001-2023: an epidemiological analysis using World Health Organization mortality dataKeith Pardillada Belangoy, Yoshito Nishimura, Ko Harada, et al.
Cancer Science|December 20, 2019
YES1 activation induces acquired resistance to neratinib in HER2-amplified breast and lung cancersTatsuaki Takeda, Hiromasa Yamamoto, Ken Suzawa, et al.
Pageof 3